Fresenius SE & Co. (FSNUY) Expected to Release Earnings on Wednesday

Fresenius SE & Co. (OTCMKTS:FSNUY) will likely be posting its results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.2156 per share and revenue of $6.51 billion for the quarter.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. On average, analysts expect Fresenius SE & Co. to post $1.04 EPS for the current fiscal year and $1.11 EPS for the next fiscal year.

Fresenius SE & Co. Stock Performance

OTCMKTS:FSNUY opened at $13.35 on Monday. The business has a 50 day moving average of $12.89 and a 200 day moving average of $12.87. The company has a market capitalization of $30.08 billion, a price-to-earnings ratio of 16.90 and a beta of 0.63. Fresenius SE & Co. has a 1-year low of $10.33 and a 1-year high of $33.93. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97.

Wall Street Analyst Weigh In

Several research analysts have commented on FSNUY shares. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.